DocDollars

Novo Nordisk As

Denmark · Reporting entity ID 100000000163

Total reported 2019–2025
$490.0M
#37 of 2,960 reporting companies — 0.6% of all reported industry payments
$74.5M in general payments across 5,214 records, plus $415.5M in research funding across 577,159 records.

How it breaks down

General payments $74,522,443
Research funding $415,518,413

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Novo Nordisk As reported $490.0M to US doctors and teaching hospitals from 2019 to 2025, ranking #37 of 2,960 reporting companies. 85% of that was research funding and 15% general payments such as consulting, speaking, food and travel. 5,214 general payment records and 577,159 research records were filed.

Common questions about Novo Nordisk As

How much has Novo Nordisk As paid US doctors?

Novo Nordisk As reported $490,040,856 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $74,522,443 in general payments, $415,518,413 in research funding.

How does Novo Nordisk As rank among drug and device companies?

It ranks #37 of 2,960 reporting entities by total reported value, about 0.6% of all industry payments in the dataset.

Does a payment from Novo Nordisk As mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.